ETV2 regulating PHD2-HIF-1α axis controls metabolism reprogramming promotes vascularized bone regeneration

• DOI: 10.1016/j.bioactmat.2024.02.014
• Publication Date: 2024-03-22T16:48:25Z
• Authors: HaoRan Du; Bang Li; Rui Yu; Xiaoxuan Lu; ChengLin Li; HuiHui Zhang; Fan Yang; RongQuan Zhao; WeiMin Bao; Xuan Yin; YuanYin Wang; Jian Zhou; Jianguang Xu
• Keywords: Microsphere; Metabolism reprogramming; 0303 health sciences; 03 medical and health sciences; QH301-705.5; Hypoxia-inducible factor-1α; ETV2; TA401-492; Vascularized bone regeneration; Biology (General); Materials of engineering and construction. Mechanics of materials; Article

The synchronized development of mineralized bone and blood vessels is a fundamental requirement for successful bone tissue regeneration. Adequate energy production forms the cornerstone supporting new bone formation. ETS variant 2 (ETV2) has been identified as a transcription factor that promotes energy metabolism reprogramming and facilitates the coordination between osteogenesis and angiogenesis. In vitro molecular experiments have demonstrated that ETV2 enhances osteogenic differentiation of dental pulp stem cells (DPSCs) by regulating the ETV2- prolyl hydroxylase 2 (PHD2)- hypoxia-inducible factor-1α (HIF-1α)- vascular endothelial growth factor A (VEGFA) axis. Notably, ETV2 achieves the rapid reprogramming of energy metabolism by simultaneously accelerating mitochondrial aerobic respiration and glycolysis, thus fulfilling the energy requirements essential to expedite osteogenic differentiation. Furthermore, decreased α-ketoglutarate release from ETV2-modified DPSCs contributes to microcirculation reconstruction. Additionally, we engineered hydroxyapatite/chitosan microspheres (HA/CS MS) with biomimetic nanostructures to facilitate multiple ETV2-DPSC functions and further enhanced the osteogenic differentiation. Animal experiments have validated the synergistic effect of ETV2-modified DPSCs and HA/CS MS in promoting the critical-size bone defect regeneration. In summary, this study offers a novel treatment approach for vascularized bone tissue regeneration that relies on energy metabolism activation and the maintenance of a stable local hypoxia signaling state.